当前位置: 首页 > 期刊 > 《医学信息》 > 2018年第17期
编号:13305910
吸入型糖皮质激素治疗儿童哮喘有效性与安全性的临床研究(1)
http://www.100md.com 2018年4月30日 《医学信息》 2018年第17期
     摘 要:目的 研究吸入型糖皮质激素治疗儿童哮喘的有效性与安全性。方法 回顾分析在我院接受治疗的96例哮喘儿童临床资料,随机分为对照组和治疗组,每组48例。取同期健康儿童40例为正常组。对照组口服醋酸泼尼松片治疗,治疗组雾化吸入布地奈德治疗,对比两组患儿治疗总有效率、肺功能指标、临床症状消退时间,以及吸入糖皮质激素对患儿身高、体重的影响。结果 治疗组治疗总有效率为97.87%,高于对照组的80.85%,差异有统计学意义(P<0.05);治疗组VCmax、FEV1、FEV1/FVC改善优于对照组,差异有统计学意义(P<0.05);治疗组咳嗽、憋喘、哮鸣音消退时间短于对照组,差异有统计学意义(P<0.05);治疗后,治疗组患儿身高、体重与正常组对比,差异无统计学意义(P>0.05)。结论 吸入型糖皮质激素治疗儿童哮喘疗效确切,可快速减轻临床症状,改善肺功能,且对患者无不良影响。

    关键词:吸入型糖皮质激素;儿童哮喘;肺功能指标

    中图分类号:R725.6 文献标识码:A DOI:10.3969/j.issn.1006-1959.2018.17.039
, 百拇医药
    文章编号:1006-1959(2018)17-0128-02

    Abstract:Objective To study the efficacy and safety of inhaled corticosteroids in the treatment of asthma in children.Methods The clinical data of 96 children with asthma who were treated in our hospital were retrospectively analyzed and randomly divided into control group and treatment group,48 cases in each group.40 healthy children in the same period were taken as normal group.The control group was treated with oral prednisone acetate.The treatment group was treated with aerosolized budesonide.The total effective rate of treatment,lung function index,time of clinical symptom regression,and the effect of inhaled corticosteroids on height and weight of children were compared.Results The total effective rate of treatment group was 97.87%,which was higher than that of the control group 80.85%,the difference was statistically significant(P<0.05).The improvement of VCmax,FEV1 and FEV1/FVC in the treatment group was better than that of the control group,the difference was statistically significant(P<0.05);the treatment group had shorter cough, asthma and wheezing time than the control group,the difference was statistically significant(P<0.05),after treatment,there was no significant difference in height and weight between the treatment group and the normal group(P>0.05).Conclusion Inhaled corticosteroids are effective in the treatment of children with asthma,which can quickly alleviate clinical symptoms,improve lung function,and have no adverse effects on patients.
, 百拇医药
    Key words:Inhaled corticosteroids;Childhood asthma;Pulmonary function indicators

    兒童哮喘是临床常见的呼吸道疾病,具有长期反复发作的特点,如果不及时治疗和控制,会造成不可逆的危害,严重时会发展成为肺气肿、肺心病,临床单纯药物治疗难以治愈[1]。所以,临床积极有效的治疗儿童哮喘具有重要的临床意义。临床常规治疗采用糖皮质激素、受体激动剂治疗,虽然具有一定的疗效,但临床症状消退时间长,且不良反应多,严重影响临床治疗效果。本文作者结合2016年8月~2017年8月在我院接受治疗的96例哮喘儿童临床资料,研究吸入型糖皮质激素治疗儿童哮喘有效性与安全性,现报告如下。

    1资料与方法

    1.1一般资料 回顾分析2016年8月~2017年8月在天津市河东区人民医院接受治疗的96例哮喘儿童临床资料,所有患儿家属均签署知情同意书。按照随机数字表法将患儿分为对照组和治疗组,每组48例。对照组男性26例,女性22例;年龄1~12岁,平均年龄(9.33±2.11)岁;轻度22例,中度16例,重度10例;病程3个月~4年,平均病程(2.80±1.15)年。治疗组男性25例,女性23例;年龄2~12岁,平均年龄(9.01±1.89)岁;轻度25例,中度15例,重度8例;病程2个月~4年,平均病程(2.96±1.10)年。取同期入院体检的健康儿童40例作为正常组,男性24例,女性16例,年龄1~12岁,平均年龄(8.80±2.05)岁。三组在年龄、性别等基础资料方面比较,差异无统计学意义(P>0.05),具有可比性。, 百拇医药(王会)
1 2下一页